Is Pmv Pharmaceuticals Stock a Good Investment?
Pmv Pharmaceuticals Investment Advice | PMVP |
- Examine Pmv Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Pmv Pharmaceuticals' leadership team and their track record. Good management can help Pmv Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Pmv Pharmaceuticals' business and its evolving consumer preferences.
- Compare Pmv Pharmaceuticals' performance and market position to its competitors. Analyze how Pmv Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Pmv Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Pmv Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Pmv Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Pmv Pharmaceuticals is a good investment.
Sell | Buy |
Sell
Market Performance | Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Pmv Pharmaceuticals Stock
Researching Pmv Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 81.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.42. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pmv Pharmaceuticals recorded a loss per share of 1.0. The entity had not issued any dividends in recent years.
To determine if Pmv Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pmv Pharmaceuticals' research are outlined below:
| Pmv Pharmaceuticals may become a speculative penny stock | |
| Pmv Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (68.96 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Pmv Pharmaceuticals currently holds about 277.43 M in cash with (55.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Pmv Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 81.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: PMV Pharmaceuticals files 200M mixed securities shelf - TipRanks |
Pmv Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Pmv Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pmv Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Pmv Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Pmv Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-11-12 | 2021-09-30 | -0.3 | -0.33 | -0.03 | 10 | ||
2022-03-01 | 2021-12-31 | -0.35 | -0.4 | -0.05 | 14 | ||
2024-05-09 | 2024-03-31 | -0.36 | -0.3 | 0.06 | 16 | ||
2024-02-29 | 2023-12-31 | -0.39 | -0.31 | 0.08 | 20 | ||
2023-08-09 | 2023-06-30 | -0.47 | -0.38 | 0.09 | 19 | ||
2023-11-09 | 2023-09-30 | -0.45 | -0.34 | 0.11 | 24 | ||
2024-08-08 | 2024-06-30 | -0.35 | -0.02 | 0.33 | 94 | ||
2021-03-03 | 2020-12-31 | -0.57 | -0.23 | 0.34 | 59 |
Know Pmv Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pmv Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pmv Pharmaceuticals backward and forwards among themselves. Pmv Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Pmv Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goldman Sachs Group Inc | 2024-06-30 | 808.7 K | Millennium Management Llc | 2024-06-30 | 758.7 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 705.6 K | Personal Cfo Solutions, Llc | 2024-06-30 | 550.3 K | Citigroup Inc | 2024-09-30 | 514.9 K | Two Sigma Advisers, Llc | 2024-06-30 | 493.5 K | Two Sigma Investments Llc | 2024-09-30 | 483.1 K | Barclays Plc | 2024-06-30 | 465 K | Acuitas Investments, Llc | 2024-09-30 | 440.7 K | Orbimed Advisors, Llc | 2024-06-30 | 6.5 M | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 3.6 M |
Pmv Pharmaceuticals' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 82.28 M.Market Cap |
|
Pmv Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.27) | (0.29) | |
| Return On Capital Employed | (0.34) | (0.35) | |
| Return On Assets | (0.27) | (0.29) | |
| Return On Equity | (0.31) | (0.29) |
Determining Pmv Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Pmv Pharmaceuticals is a good buy. For example, gross profit margin measures Pmv Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Pmv Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Pmv Pharmaceuticals' management efficiency
Pmv Pharmaceuticals has return on total asset (ROA) of (0.2027) % which means that it has lost $0.2027 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2363) %, meaning that it created substantial loss on money invested by shareholders. Pmv Pharmaceuticals' management efficiency ratios could be used to measure how well Pmv Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/26/2024, Return On Tangible Assets is likely to drop to -0.29. In addition to that, Return On Capital Employed is likely to drop to -0.35. At this time, Pmv Pharmaceuticals' Liabilities And Stockholders Equity is relatively stable compared to the past year. As of 11/26/2024, Non Current Liabilities Other is likely to grow to about 16.2 M, while Total Current Liabilities is likely to drop slightly above 9.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.70 | 2.91 | |
| Tangible Book Value Per Share | 4.70 | 2.91 | |
| Enterprise Value Over EBITDA | (1.58) | (1.66) | |
| Price Book Value Ratio | 0.66 | 0.69 | |
| Enterprise Value Multiple | (1.58) | (1.66) | |
| Price Fair Value | 0.66 | 0.69 | |
| Enterprise Value | 347.7 M | 330.3 M |
The leadership approach at Pmv Pharmaceuticals' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Beta 1.484 |
Basic technical analysis of Pmv Stock
As of the 26th of November, Pmv Pharmaceuticals holds the Coefficient Of Variation of 3605.69, semi deviation of 2.0, and Risk Adjusted Performance of 0.028. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pmv Pharmaceuticals, as well as the relationship between them.Pmv Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pmv Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pmv Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pmv Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pmv Pharmaceuticals' Outstanding Corporate Bonds
Pmv Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pmv Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pmv bonds can be classified according to their maturity, which is the date when Pmv Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US69354NAD84 Corp BondUS69354NAD84 | View | |
| PRAA 8375 01 FEB 28 Corp BondUS69354NAE67 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| US69356NAA28 Corp BondUS69356NAA28 | View | |
| PPL 739486 30 MAR 67 Corp BondUS69352PAC77 | View | |
| PPL CAP FDG Corp BondUS69352PAL76 | View | |
| PPG 12 15 MAR 26 Corp BondUS693506BU04 | View |
Understand Pmv Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Pmv Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.028 | |||
| Market Risk Adjusted Performance | 0.1109 | |||
| Mean Deviation | 1.61 | |||
| Semi Deviation | 2.0 | |||
| Downside Deviation | 2.41 | |||
| Coefficient Of Variation | 3605.69 | |||
| Standard Deviation | 2.42 | |||
| Variance | 5.86 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.32) | |||
| Sortino Ratio | (0.03) | |||
| Treynor Ratio | 0.1009 | |||
| Maximum Drawdown | 13.98 | |||
| Value At Risk | (3.64) | |||
| Potential Upside | 3.75 | |||
| Downside Variance | 5.79 | |||
| Semi Variance | 4.0 | |||
| Expected Short fall | (1.97) | |||
| Skewness | 0.782 | |||
| Kurtosis | 2.89 |
| Risk Adjusted Performance | 0.028 | |||
| Market Risk Adjusted Performance | 0.1109 | |||
| Mean Deviation | 1.61 | |||
| Semi Deviation | 2.0 | |||
| Downside Deviation | 2.41 | |||
| Coefficient Of Variation | 3605.69 | |||
| Standard Deviation | 2.42 | |||
| Variance | 5.86 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.32) | |||
| Sortino Ratio | (0.03) | |||
| Treynor Ratio | 0.1009 | |||
| Maximum Drawdown | 13.98 | |||
| Value At Risk | (3.64) | |||
| Potential Upside | 3.75 | |||
| Downside Variance | 5.79 | |||
| Semi Variance | 4.0 | |||
| Expected Short fall | (1.97) | |||
| Skewness | 0.782 | |||
| Kurtosis | 2.89 |
Consider Pmv Pharmaceuticals' intraday indicators
Pmv Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pmv Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Pmv Pharmaceuticals time-series forecasting models is one of many Pmv Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Pmv Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Pmv Stock media impact
Far too much social signal, news, headlines, and media speculation about Pmv Pharmaceuticals that are available to investors today. That information is available publicly through Pmv media outlets and privately through word of mouth or via Pmv internal channels. However, regardless of the origin, that massive amount of Pmv data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Pmv Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pmv Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pmv Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pmv Pharmaceuticals alpha.
Pmv Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Pmv Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Pmv Pharmaceuticals Corporate Management
| Laura Leon | VP Operations | Profile | |
| Leila MD | Chief Officer | Profile | |
| Winston MBA | COO CFO | Profile | |
| Marc MD | Senior Affairs | Profile | |
| Tim Smith | Senior Relations | Profile | |
| Robert Ticktin | Head Counsel | Profile | |
| Deepika PharmD | Chief Officer | Profile |
Additional Tools for Pmv Stock Analysis
When running Pmv Pharmaceuticals' price analysis, check to measure Pmv Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pmv Pharmaceuticals is operating at the current time. Most of Pmv Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pmv Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pmv Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pmv Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.